Publications
Detailed Information
Expression of mTOR protein and its clinical significance in endometrial cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | No, Jae Hong | - |
dc.contributor.author | Jeon, Yong-Tark | - |
dc.contributor.author | Park, In-Ae | - |
dc.contributor.author | Kang, Daehee | - |
dc.contributor.author | Park, Noh-Hyun | - |
dc.contributor.author | Song, Yong-Sang | - |
dc.contributor.author | Kang, Soon-Beom | - |
dc.contributor.author | Kim, Jae Weon | - |
dc.date.accessioned | 2012-06-28T02:01:26Z | - |
dc.date.available | 2012-06-28T02:01:26Z | - |
dc.date.issued | 2009-10 | - |
dc.identifier.citation | MEDICAL SCIENCE MONITOR; Vol.15 10; BR301-BR305 | ko_KR |
dc.identifier.issn | 1234-1010 | - |
dc.identifier.uri | https://hdl.handle.net/10371/77720 | - |
dc.description.abstract | Background: Mammalian target of rapamycin (mTOR) plays a crucial role in carcinogenesis by regulating protein synthesis, and mTOR inhibitors have been identified as potential anticancer agents in various cancers. Since the most common genetic change in endometrial cancer is the mutation of phosphatase and tensin homologue (PTEN), a negative regulator of mTOR, we evaluated mTOR expression in endometrial cancer and its relationship with other clinicopathological characteristics and expression patterns of cyclooxygenase-2 (COX-2) and p53. Material/Methods: Immunohistochemical analysis of mTOR was performed on paraffin-embedded tissue specimens obtained from 141 patients with endometrial carcinoma. Results were correlated with the clinicopathological pathological characteristics and expression pattern of COX-2 and p53. Results: mTOR overexpression was detected in 7.1% (10/141) of patients. mTOR expression was highly correlated with old age, menopausal status and COX-2 expression (p<0.05). Multivariate analysis revealed that COX-2 was the only independent factor related to expression of mTOR. However, there was no correlation of mTOR expression with prognostic factors such as histologic type, grade, invasion of myometrium, lymph node metastasis, stage, and survival. Conclusions: Our findings suggest that the expression of mTOR is infrequent. and is associated with COX-2 overexpression. Careful selection of patients might be necessary in the use of mTOR inhibitor as a molecular targeted therapy for patients with endometrial cancer. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | INT SCIENTIFIC LITERATURE, INC | ko_KR |
dc.subject | mTOR | ko_KR |
dc.subject | endometrial cancer | ko_KR |
dc.subject | immunohistochemistry | ko_KR |
dc.title | Expression of mTOR protein and its clinical significance in endometrial cancer | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 노재홍 | - |
dc.contributor.AlternativeAuthor | 전용탁 | - |
dc.contributor.AlternativeAuthor | 박인애 | - |
dc.contributor.AlternativeAuthor | 강대희 | - |
dc.contributor.AlternativeAuthor | 김재원 | - |
dc.contributor.AlternativeAuthor | 박노현 | - |
dc.contributor.AlternativeAuthor | 강순범 | - |
dc.contributor.AlternativeAuthor | 송용상 | - |
dc.citation.journaltitle | MEDICAL SCIENCE MONITOR | - |
dc.description.citedreference | Han SS, 2008, MED SCI MONITOR, V14, pCR183 | - |
dc.description.citedreference | Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010 | - |
dc.description.citedreference | Chiang GG, 2007, TRENDS MOL MED, V13, P433, DOI 10.1016/j.molmed.2007.08.001 | - |
dc.description.citedreference | Blanco-Aparicio C, 2007, CARCINOGENESIS, V28, P1379, DOI 10.1093/carcin/bgm052 | - |
dc.description.citedreference | Pantuck AJ, 2007, CANCER, V109, P2257, DOI 10.1002/cncr.22677 | - |
dc.description.citedreference | Hudes G, 2007, NEW ENGL J MED, V356, P2271 | - |
dc.description.citedreference | Sieghart W, 2007, TRANSPLANTATION, V83, P425, DOI 10.1097/01.tp.0000252780.42104.95 | - |
dc.description.citedreference | Leseux L, 2006, BLOOD, V108, P4156, DOI 10.1182/blood-2006-05-026203 | - |
dc.description.citedreference | Corradetti MN, 2006, ONCOGENE, V25, P6347, DOI 10.1038/sj.onc.1209885 | - |
dc.description.citedreference | Mamane Y, 2006, ONCOGENE, V25, P6416, DOI 10.1038/sj.onc.1209888 | - |
dc.description.citedreference | Easton JB, 2006, ONCOGENE, V25, P6436, DOI 10.1038/sj.onc.1209886 | - |
dc.description.citedreference | Treeck O, 2006, GYNECOL ONCOL, V102, P292, DOI 10.1016/j.ygyno.2005.12.019 | - |
dc.description.citedreference | Slipicevic A, 2005, AM J CLIN PATHOL, V124, P528, DOI 10.1309/YT58WWMTA6YR1PRV | - |
dc.description.citedreference | Morgensztern D, 2005, ANTI-CANCER DRUG, V16, P797 | - |
dc.description.citedreference | Vignot S, 2005, ANN ONCOL, V16, P525, DOI 10.1093/annonc/mdi113 | - |
dc.description.citedreference | Jeon YT, 2004, CANCER EPIDEM BIOMAR, V13, P1538 | - |
dc.description.citedreference | Panigrahi AR, 2004, J PATHOL, V204, P93, DOI 10.1002/path.1611 | - |
dc.description.citedreference | Sansal I, 2004, J CLIN ONCOL, V22, P2954, DOI 10.1200/jco.2004.02.141 | - |
dc.description.citedreference | St-Germain ME, 2004, INT J ONCOL, V24, P1311 | - |
dc.description.citedreference | Neeli I, 2003, BIOCHEM BIOPH RES CO, V309, P755, DOI 10.1016/j.bbrc.2003.08.066 | - |
dc.description.citedreference | Zhou CX, 2003, MOL CANCER THER, V2, P789 | - |
dc.description.citedreference | Terakawa N, 2003, ENDOCR-RELAT CANCER, V10, P203 | - |
dc.description.citedreference | Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015 | - |
dc.description.citedreference | An HJ, 2002, HISTOPATHOLOGY, V41, P437 | - |
dc.description.citedreference | Mutter GL, 2000, J NATL CANCER I, V92, P924 | - |
dc.description.citedreference | Di Cristofano A, 2000, CELL, V100, P387 | - |
dc.description.citedreference | Risinger JI, 1998, CLIN CANCER RES, V4, P3005 | - |
dc.description.citedreference | Risinger JI, 1997, CANCER RES, V57, P4736 | - |
dc.description.citedreference | Kong DH, 1997, NAT GENET, V17, P143 | - |
dc.description.tc | 5 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.